Gary John Schiller
Impact in
- Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Genetics top 0.2%
Papers in
- Hematology 266
- Acute Myeloid Leukemia Research 154
- Multiple Myeloma Research and Treatments 75
- Hematopoietic Stem Cell Transplantation 68
- Chronic Myeloid Leukemia Treatments 59
- Genetics 75
- Myeloproliferative Neoplasms: Diagnosis and Treatment 32
- Co-authors
- Mary Territo (25 shared papers)Alan K. Lichtenstein (5 shared papers)Erika V. Valore (1 shared paper)Tomas Ganz (1 shared paper)Elizabeta Nemeth (1 shared paper)John F. DiPersio (6 shared papers)Amanda F. Cashen (3 shared papers)Margaret R O'Donnell (2 shared papers)
- Journals
- Blood (115 papers)Transplantation and Cellular Therapy (36 papers)Journal of Clinical Oncology (22 papers)Leukemia (15 papers)Blood Advances (11 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Gary John Schiller
375 papers receiving 18.1k citations
Gary John Schiller's Hit Papers
Peers
Comparison fields: 5 of 149
- Hematology 10.3k
- Genetics 3.2k
- Oncology 4.8k
- Public Health, Environmental and Occupational Health 2.4k
- Immunology 1.8k
Countries citing papers authored by Gary John Schiller
This map shows the geographic impact of Gary John Schiller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary John Schiller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary John Schiller more than expected).
Fields of papers citing papers by Gary John Schiller
This network shows the impact of papers produced by Gary John Schiller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary John Schiller. The network helps show where Gary John Schiller may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary John Schiller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 392 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Hit paper breakdown → | 2003 | 1231 |
| 2 | Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2014 | 1068 |
| 3 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Hit paper breakdown → | 2018 | 791 |
| 4 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Hit paper breakdown → | 2021 | 627 |
| 5 | Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia Hit paper breakdown → | 2018 | 549 |
| 6 | Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma Hit paper breakdown → | 2019 | 513 |
| 7 | 2005 | 471 | |
| 8 | 2010 | 441 | |
| 9 | 1997 | 419 | |
| 10 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Hit paper breakdown → | 2017 | 414 |
| 11 | 2009 | 405 | |
| 12 | 2010 | 370 | |
| 13 | 2012 | 250 | |
| 14 | 2005 | 239 | |
| 15 | 1995 | 227 | |
| 16 | 2009 | 212 | |
| 17 | 2000 | 209 | |
| 18 | 2018 | 199 | |
| 19 | 2006 | 187 | |
| 20 | 2012 | 167 |
About Gary John Schiller
Gary John Schiller is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 392 papers that have together received 18.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (154 papers), Multiple Myeloma Research and Treatments (75 papers), Hematopoietic Stem Cell Transplantation (68 papers), Acute Lymphoblastic Leukemia research (63 papers), Chronic Myeloid Leukemia Treatments (59 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Protein Degradation and Inhibitors (31 papers) and CAR-T cell therapy research (30 papers). The work is most often cited by research in Hematology (10.3k citations), Genetics (3.2k citations), Oncology (4.8k citations), Public Health, Environmental and Occupational Health (2.4k citations) and Immunology (1.8k citations). Gary John Schiller has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Mary Territo, Alan K. Lichtenstein, Erika V. Valore, Tomas Ganz, Elizabeta Nemeth, John F. DiPersio, Amanda F. Cashen, Margaret R O'Donnell, Drew J. Winston and Robert Allen Vescio. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, Journal of Clinical Oncology, Leukemia and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.